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Abstract 
Objectives 
To identify guidelines and assessment tools used by health technology agencies for 
quality assurance of registers and investigate the current use of register data by HTA 
organisations worldwide. 
Methods 
As part of a European Network for Health Technology Assessment Joint Action work 
package, we undertook a literature search and sent a questionnaire to all partner 
organisations on the work package and all organisations listed in the International 
Society for Pharmaco-economics and Outcomes Research directory. 
Results 
We received 55 responses from organisations representing 21 different countries, a 
response rate of 40.5% (43/110). Many agencies – particularly in Europe - are already 
drawing on a range of registries to provide data for their HTA. Less than half, however, 
employ criteria or standards to assess the quality of registry data. Nearly all criteria or 
standards in use have been internally defined by organisations rather than referring to 
those produced by an external body. We identified thirteen relevant documents 
relating to quality assurance of registers. A comparison of internal and external 
standards identified consistency in several quality dimensions, which can be used as 
a starting point for the development of a standardised tool.  
Conclusion 
The use of register data is more prevalent than expected, strengthening the need for 
a standardised register quality assessment tool. A user-friendly tool developed in 
conjunction with stakeholders will support the consistent application of approved 
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quality standards, and reassure critics who have traditionally considered registry data 
to be unreliable. 
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Introduction 
 
The use of registers and registries is becoming increasingly common in health 
technology assessment (HTA) as interest grows in the use of observational data to 
complement experimental data and to accelerate the process of access to new 
technologies (1). Registries have been defined as “an organized system that collects, 
analyses, and disseminates the data and information on a group of people defined by 
a particular disease, condition, exposure, or health-related service, and that serves a 
predetermined scientific, clinical or/and public health (policy) purposes (2).  The quality 
of registry data has often been criticised, however, leading to reluctance to embed 
their use in HTA (3-5).  While there are several guides to improving observational data 
collection and reporting, there is no standardised tool for use by HTA agencies to 
assess registry quality (6-8). 
 
The European network for Health Technology Assessment (EUnetHTA) has been 
working through a series of work packages of its Joint Action 3 (2016 – 2019; referred 
to as EUnetHTA JA3) to enhance the use of high-quality registries in HTA. The 
purpose of one of these work packages (Work Package 5 Strand B) is the production 
of a standardised tool for the use of registries in HTA, based on the “Methodological 
guidance on the efficient and rational governance of registries” (referred to here as the 
PARENT Guidelines) (2). The PARENT guidelines describe important dimensions in 
assessing the quality of registries, including governance, data quality, information 
quality and data protection (Table 1). The aim of the guidelines was to support EU 
Member States in developing comparable and interoperable patient registries in fields 
of identified importance (e.g. chronic and rare diseases, medical technology) with the 
aim to rationalise the development and governance of patient registries, thus enabling  
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Table 1: Recommendations for registries from the PARENT guidelines 
Dimension Subdimension Criterion Indicator(s) 
G
O
VE
R
N
A
N
C
E 
Procedures and 
methods for 
registry operation 
and governance 
Clearly stated purpose, structures, 
protocol/ procedures and 
information governance policies 
Registry manual 
Formal plan for registry 
governance and oversight 
covering overall direction and 
operations, scientific content, 
ethics, safety, data access, 
publications, and change 
management. 
Education and 
training 
Registry staff as well as data 
providers should receive formal and 
refresher training on registry 
procedures 
Training plan and record of 
training sessions 
Resource 
planning and 
financial 
sustainability 
Resources should be adequate to 
ensure the sustainability, continual 
relevance and maximum impact of 
the data for which the registry 
holders are responsible 
Registry size and duration 
defined 
Interoperability 
Interoperability principles should be 
applied to all aspects of registry 
including establishment, 
development, operation, use and 
governance to support national and 
international collaboration 
Use of semantic standards, 
models and tools 
Procedures for granting access to 
or sharing data (nationally or 
internationally) in place, including 
response time targets 
Self-assessment 
Self-assessment should serve to 
identify sources of potential data 
quality issues and assess them by 
using indicators on data quality 
dimensions, developing 
measurements for evaluation, 
subsequently used to correct 
issues and track improvements 
(essentially data/quality 
improvement) 
Formal audit and quality 
assurance plan 
Establishment of a Quality 
Assurance Committee 
Expert guidance 
The establishment of an Advisory 
Board consisting of a 
knowledgeable panel with expertise 
relevant to the registry domain and 
committed to the registry 
Establishment of Advisory Board 
D
A
TA
 Q
U
A
LI
TY
 
Accuracy 
How well information in or derived 
from the data reflects the reality it 
was designed to measure 
Validity exercise against gold 
standard 
Completeness 
Extent to which all necessary data 
that could have registered have 
actually been registered (coverage) 
 
Interpretability 
and Accessibility 
This includes the ease with which 
the existence of information can be 
ascertained, the suitability of the 
form or medium through which the 
information can be accessed, 
whether data are accompanied with 
appropriate metadata and whether 
information on their quality is also 
available (including limitation in 
use, generalisability and 
representativeness of registry) 
Metadata and data dictionary 
available 
Membership of yellow-page type 
services like PARENT Joint 
Action Registry of Registries, 
AHRQ Registry of Patient 
Registries or other specialized 
“umbrella” registry 
Relevance 
The degree to which data meet the 
current and potential needs of 
users 
Stakeholder analysis 
Timeliness How current or up to date the data are at the time of release 
Average gap between end of 
reference period for data and date 
available to users 
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Coherence 
Coherence covers the internal 
consistency of data collection as 
well as its comparability both over 
time and with other data sources 
Use of standard data definitions 
and a common data element to 
enable linkage 
Mode of data 
collection and 
impact on data 
quality 
How well data collection is 
integrated into the working practice 
of data providers 
Electronic data collection 
Minimal dataset 
Data collection template 
IN
FO
R
M
A
TI
O
N
 
Q
U
AL
IT
Y 
- The extent to which registry data are being used for their original purpose 
Recent publications from registry 
data 
Data briefings/summary statistics 
available 
Establishment of Scientific 
Committee to guide scientific 
utilisation of registry data and 
assess external applications for 
utilisation of data 
Use of registry data in health 
service research/quality 
improvement/policies 
D
A
TA
 
PR
O
TE
C
TI
O
N
 
- 
The safeguards put in place to 
protect patient privacy and 
confidentiality 
Information governance policy 
Registry adheres to Data Protection 
Directive (95/46/EC) or upcoming 
European Data Protection 
Framework 
Privacy impact assessment 
 
analyses of secondary data for public health, policy and research purposes in cross-
border settings.  
 
We present here the findings from the first part of this work package, namely (i) a 
literature review to identify any existing guidelines and/or assessment tools for quality 
assurance of registers, (ii) a survey to explore the current understanding and use of 
registries by HTA agencies and particularly the employment of any standards/criteria 
or other tool to assess the quality and comparability of registries before their use in 
HTA, and (iii) an overview of the registry quality dimensions in the standards/criteria 
identified through the literature review, researchers’ prior knowledge and the survey. 
The purpose of the literature review, the survey and the overview of the guidance 
documents for registries was to feed into the development of a standardised tool to 
assess registries. 
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Methods 
The National Institute for Health and Care Excellence (NICE) in the United Kingdom 
(UK) and the Croatian Institute of Public Health (HZJZ) led this study on behalf of 
EUnetHTA JA3. We conducted a literature search, using PubMed as the literature 
database and the following search terms were used “(“technology assessment, 
biomedical”[MeSH Terms] OR (“technology”[All Fields] AND “assessment”[All Fields] 
AND “biomedical”[All Fields]) OR “biomedical technology assessment”[All Fields] OR 
(“technology”[All Fields] AND “assessment”[All Fields] AND “biomedical”[All Fields]) 
OR “technology assessment, biomedical”[All Fields]) AND (“registries”[MeSH Terms] 
OR “registries”[All Fields])”. There were no date restrictions but only articles in 
English were reviewed. A single reviewer examined titles and abstracts in order to 
identify those that referred to the use of registries for health technology assessment. 
 
An initial survey tool was developed based on discussions between NICE and HZJZ 
on the work programme objectives. Dimensions of registry use to be assessed in the 
survey included: the use of different types of registries by HTA organisations; the 
purposes for which registries were used in HTA; and the methodology and processes 
applied to assess quality of registries before use in HTA. Types of registries to be 
included in the survey were based on the PARENT Guidelines and defined as follows:  
 
 Disease/condition registries (include patients with a common disease or 
condition e.g. cystic fibrosis or cancer)  
 Pharmaceutical registries (include patients who have taken a particular 
pharmaceutical product)  
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 Medical technology registries (include patients who have been exposed to a 
particular device or diagnostic technology)  
 Procedural registries (include patients who have undergone a particular 
medical or surgical procedure)  
 
We specified purposes for which register data could be used by HTA agencies to 
reflect steps in the HTA process, namely: 
 Natural history of disease/condition 
 Evaluation of effectiveness (for example, data on the natural history of a 
disease/condition for decision modelling, or to create cohorts for comparative 
effectiveness analysis) 
 Evaluation of cost and/or budget impact (for example, cost data from 
pharmaceutical registries, current and/or potential uptake of health technology 
from disease/condition registries) 
 Future reviews of the technology, particularly where there is a lack of evidence 
for the technology (for example, safety/adverse events data from medical 
technology or procedural registries)  
 
We asked whether HTA agencies used any standards or criteria to assess the quality 
of registries before use, and if so, whether these were defined internally by the 
organisation or an external organisation. If no standards were used, we asked whether 
other steps were taken to evaluate quality of register data before use in HTA.  
 
The survey was conducted in English. Pre-testing of the survey tool was conducted 
among EUnetHTA JA3 members of NICE and HZJZ, with adjustments made to the 
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definitions of types of registries and the addition of a hyperlink to the PARENT 
wikipage on quality. A formal pilot of the survey was then conducted with two HTA 
organisations selected in order to ensure European and non-European representation, 
namely A Unidade de Asesoramento Científico-técnico (Avalia-t) in Spain and the 
Health Intervention and Technology Assessment Program (HITAP) in Thailand. 
Changes based on feedback from these organisations included the addition of a 
question on other methods to assess the quality of registries apart from quality 
standards, and revision of some wording to improve clarity for non-native English 
speakers. A final survey tool was developed to reflect these changes (see 
supplementary file 1).  
 
The final survey tool was sent by email to all EUnetHTA JA3 partner organisations and 
all HTA organisations in the International Society for Pharmaco-economics and 
Outcomes 7 Research (ISPOR) directory a total of 110 organisations (9). One 
reminder email was sent after two weeks to all organisations that had not yet 
responded. The survey was closed one month after the initial call.  
 
Participants who reported using internal standards to assess the quality of registers 
were contacted up to three more times to request that they provide a copy of those 
standards for review. We compared the criteria listed in the external and internal 
standards obtained, to the recommendations of the PARENT project. 
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RESULTS  
The literature review returned 96 titles and abstracts that met the inclusion criteria, 
from which we identified 22 relevant publications. The review identified no standards 
or guidelines specifically relating to the use of registries for HTA, however several 
described attributes of high quality registers which we discuss further below.   
 
We received 55 responses to the survey from organisations representing 21 different 
countries, a response rate of 40.5% (43/110). One organisation was excluded as it 
does not undertake HTA (Semmelweis University Health Services Management 
Training Centre in Hungary). Two responses were received from six organisations: the 
Canadian Agency for Drugs and Technologies in Health (CADTH), Finnish Medicines 
Agency (FIMEA), Association of Austrian Social Insurance Institutions (HVB), Scottish 
Medicines Consortium, Belgian Health Care Knowledge Centre (KCE) and Swedish 
Dental and Pharmaceutical Benefits Agency (TLV). For these organisations, we used 
the first response received for analysis.  
 
Responses were received from across Europe (see Figure 1 in the supplementary 
material on line). Agencies in Canada and Thailand also provided input. Responses 
were received from 33 out of a total 78 (42%) EUnetHTA partners. No responses were 
received from HTA organisations based in Latin America, Africa or Australasia.  
 
Disease/condition registries were the most common type of registry used in HTA, with 
nearly three quarters of responding organisations using these registries compared to 
half or less using pharmaceutical, medical technology or procedural registries (Table 
2). Other types of registries used in HTA included health expenditure databases such 
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as reimbursement or insurance data, pharmaceutical or medical technology wholesale 
data; clinical trials registries; and routine databases for usual care.  
 
Table 2 Types of registers used in health technology assessment 
Type of registry Number of organisations using registry in HTA (%) 
Disease/condition 30/41 (73.2) 
Pharmaceutical 21/41 (51.2) 
Medical technology 20/41 (48.8) 
Procedural 17/41 (41.5) 
Other 8/41 (19.5) 
 
 
Effectiveness data and estimation of the current and/or potential uptake of a health 
technology were the two most common uses of registry data, with over two thirds of 
responding organisations employing registry data for these purposes (Table 3). Nearly 
two thirds of organisations were using registry data to estimate safety or adverse 
events. Registries were also being used by around one in two organisations to provide 
data on costs, the natural history of a disease or condition and cohorts for comparative 
effectiveness analysis. Other uses included assessment of comorbidities and patient 
characteristics for managed entry agreements and to monitor the appropriate use of 
pharmaceuticals post-launch.  
 
Sixteen organisations report that they use criteria or standards to assess the quality 
of registry data before use in HTA. Most organisations used internally defined criteria 
or standards (14/16, 87.5%) with one organisation using both internally defined and 
external criteria/standards. Of the 14 organisations that reported using internally 
defined criteria, only two made these available to the study group (Italian Arthroplasty  
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Table 3 Use of registers in health technology assessment 
Use of registry data Number of organisations 
using registry data in HTA 
(%) 
Effectiveness data   29/41 (70.7) 
Current and/or potential uptake of health technology 29/41 (70.7) 
Safety/adverse events data  27/41 (65.9) 
Cost data    21/41 (51.2) 
Natural history of disease/condition 20/41 (48.8) 
Cohort data for comparative effectiveness analysis 19/41 (46.3) 
Other 10/41 (24.4) 
 
 
Registry and NICE). The Italian Arthroplasty Registry was excluded from further 
analysis as this was a review of data in the registry, rather than criteria for assessment 
of data quality.  None of the organisations using internally defined register standards 
or criteria have published any assessments of registers using these tools. 
 
For those organisations not employing criteria or standards to assess the quality of 
registry data, nearly one in two used discussion with experts (13/27, 48.1%) and one 
in three used discussion with stakeholders (9/27, 33.3%). One in five (6/27, 22.2%) 
inspected registry data directly before use in HTA. One organisation noted what 
information was lacking in existing registry studies. Another highlighted that there were 
no specific quality standards available for registries.  
 
The literature review, researchers’ prior knowledge and the survey, identified 13 
guidance documents for registries (2,7-19); Methodological guidelines and 
recommendations for efficient and rational governance of patient registries (PARENT) 
  13 of 21 
(2), Use of Real-World Evidence to Support Regulatory Decision-Making for Medical 
Devices (FDA) (7), Recommendations for the development and operation of health-
related registries (ANQ) (8), ISPOR Directory of HTA organisations worldwide 
(ISPOR) (9), Medical Device Registries - Six Key Principles (EUCOMED) (10), 
Evaluating databases - Interventional procedures programme (REBIP) (11), Principles 
of International System of Registries Linked to Other Data Sources and Tools (IMDRF) 
(12), Interventional procedures programme manual (NICE) (13)  Registries for 
evaluating patient outcomes: A user’s guide (AHRQ) (14), Operating Principles and 
Technical Standards for Australian Clinical Quality Registries (ACSQHC) (15), Data 
Quality, Validation and Data Source Integration in Rare Disease Registries (EPIRARE) 
(16), The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) Statement: guidelines for reporting observational studies (17), A Validated 
Checklist for Evaluating the Quality of Observational Cohort Studies for Decision-
Making Support (GRACE Initiative) (18), Registry Studies: Why and How (19). 
 
These publications differed in their scope (real world data sources vs. patient registries 
in general vs. specific type of patient registry), purpose (conducting vs. reporting vs. 
evaluating research), dimensions covered (design and conduct vs. quality dimensions 
such as governance, data quality and safety), or format (checklist vs. explanatory 
form). Three of the 13 guidance documents were excluded from further analysis 
because they focused on retrospective evaluation of design and conduct of a registry 
rather than prospective quality dimensions (17,18) or were based (19) on another 
guidance document (14). Table 4 provides a comparison of the included nine quality 
guidance documents against the dimensions described in the PARENT guidelines. 
For clarity, we have not provided the reference number of each corresponding criterion 
for each guidance, which are instead available in the supplementary online material 
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(along with summary details of each of the guidance documents in Suppl. Tables 1-
12). Comparison is made against the PARENT guidelines, as these served as a 
starting point for the development of a standardised register quality assessment tool, 
for which this work acted as additional input. Table 4 shows wide variation in the 
criteria covered across all standards. Only the AHRQ standards covering all the quality 
dimensions outlined in the PARENT guidelines, with the internal NICE standards 
showing the fewest corresponding criteria. The most commonly mentioned areas 
across the guidelines are; Procedures and methods for registry operation and 
governance, Self-assessment, Data accuracy and completeness, Mode of data 
collection and impact on data quality, and Legal and ethical issues. With such 
consistency across guidelines, these areas could be viewed as essential quality 
criteria for education and training. Resource planning, Interpretable and accessible 
data, and Information quality (in terms of data briefings or recent publications) were 
omitted the most and could be viewed as optional quality criteria. . Interoperability, the 
key element to PARENT endeavours, was covered or explained in 6 of the 9 
guidelines, and it is mostly presented as semantic or technical interoperability, rather 
than being described through all five interconnected levels as it stands in the European 
Interoperability Framework and PARENT guidelines. 
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Table 4 Comparison of PARENT recommendations with nine relevant published guidance documents 
 
PARENT recommendations Comparison with PARENT criterion  (number of corresponding criterion) 
Dimension Subdimension NICE Swiss standards FDA Eucomed ReBIP IMDRF ACSQHC AHRQ EPIRARE 
GOVERNANCE 
Procedures and 
methods for registry 
operation and 
governance 
 X X X X X X X X 
Education and training    X    X  
Resource planning and 
financial sustainability 
 X  X X  X X  
Interoperability  X  X  X X X X 
Self-assessment  X X X X X X X X 
Expert guidance X X   X X X X X 
DATA QUALITY 
Accuracy X X X  X X X X X 
Completeness X  X X X X X X X 
Interpretability and 
Accessibility 
  X   X X X X 
Relevance X X X    X X  
Timeliness   X    X X X 
Coherence  X X   X X X X 
Mode of data collection 
and impact on data 
quality 
 X X X  X X X X 
INFORMATION 
QUALITY - 
 X   X X X X  
CONFIDENTIALITY, 
SECURITY, 
PRIVACY, ETHICAL 
ISSUES, 
SECONDARY USE 
OF INFORMATION 
- X 
X,N/A - EU 
regulation 
not 
applicable 
in 
Switzerland 
X  X  X X X 
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DISCUSSION  
This survey of HTA organisations shows that many agencies – particularly in Europe 
- are drawing on a range of registries to provide data for their HTA. Less than half, 
however, currently employ criteria or standards to assess the quality of registry data 
before use in HTA. Nearly all criteria or standards that are being used by HTA 
organisations have been defined by their organisation, rather than a standardised tool 
published by an external body. A comparison of internal and external standards 
identified wide variation in content. However there was consistency in several quality 
criteria, which can be used as a starting point for development of a standardised tool.  
 
Registries have been recognised as an important source of data and information, both 
during the pre- as well as post-launch phases of technology lifecycle and related 
assessments, yet until now, only anecdotal evidence was available on the use of 
registries by HTA organisations in Europe (10,11). Contrary to expectations, this 
survey shows that HTA organisations are actively using registry data for complex 
decision-making in a range of areas but without reference to a standardised method 
to assess relevance and quality. Given that the use of registries is more prevalent than 
expected, this strengthens the need for a standardised tool to promote best practice 
for the collection and use of such data.  
 
The survey also identified a number of criteria/standards currently in use by HTA 
organisations. We were only able to obtain one example of internal standards in use, 
despite concerted follow-up. It is possible that the internal ‘definition’ of standards was 
not formalised and in an easily sharable form, which again supports the need for an 
accessible and rigorous tool. The challenge is to apply such standards consistently to 
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ensure that only registry data of sufficient relevance and quality influences decision-
making. A previous audit of registries using the NICE internal standards found that the 
quality of recommended registers was disappointing, with only a few registers mature 
enough to deliver evidence of sufficiently high quality to inform funding decisions (20). 
The NICE internal standards were found to be more limited than external guidelines in 
terms of quality criteria, which may have contributed to this result.  
 
Our comparison of internal and external standards provides a good starting point for 
the development of an internationally recognised, user-friendly tool that can be used 
across jurisdictions. Such a tool developed in conjunction with EUnetHTA 
stakeholders will support consistency of application, as well as reassure critics who 
have traditionally considered registry data to be unreliable for use in HTA. 
Collaboration in development of such a tool will be essential in order to achieve 
agreement around the application of terminology. For instance “completeness” is 
considered by many to be a criterion that needs to be evaluated in the context of a 
register’s purpose, recognizing that a register may attempt to collect broad data to 
meet the interests of all stakeholders but not all may be essential to the purpose of 
HTA.   The initiative must also recognise that data quality assessment and 
management for evidence generation is highly topical currently and should learn from 
other relevant work e.g. ‘Data Curation’ covers many of the principles that the tool 
should include. It has been defined as “the active and ongoing management of data 
through its life cycle of interest and usefulness to scholarship, science, and education. 
Data curation activities enable data discovery and retrieval, maintain its quality, add 
value, and provide for reuse over time, and this new field includes authentication, 
archiving, management, preservation, retrieval, and representation” (21). 
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Strengths of this research include the comprehensive piloting of the survey tool to 
ensure common interpretation among non-native English speakers. Despite this, it is 
possible that the survey was subject to variation and overlap in use of terms such as 
disease/pharmaceutical register. We included purposes of register data specific to the 
needs of HTA agencies, i.e. organisational (uptake), technological (effectiveness) or 
economical (cost) evaluation clusters, however it is possible that registers were being 
used for other purposes not picked up as relevant to this survey, e.g. epidemiological. 
Any standard developed will need to reflect the diverse current use of registers in HTA.  
 
The comprehensive distribution list used for the survey strengthened the methodology, 
but may have contributed to a fairly low response rate of 40%. Translation of the survey 
tool into other languages such as Spanish may have increased participation, for 
example from Latin American HTA agencies. Thus the results presented here should 
be seen as only an indicative picture of the relationship between HTA activity and 
registries. An alternative methodological approach, rather than identifying quality 
standards already in use, would have been to build consensus on those registers that 
are considered to produce high quality data and then to examine features that the 
corresponding registries had in common. However, many registers only capture data 
from one jurisdiction and therefore it seemed likely that these features would be 
already captured in jurisdiction-specific quality standards. 
  
In conclusion, many HTA agencies are already using register data, despite the lack of 
a standardised quality assessment tool.  A review of existing standards found wide 
variation in content, but some consistency in included and omitted criteria. These 
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findings will be taken into consideration during the development of the EUnetHTA 
registries for HTA tool.  
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